Silica Nanoparticles For Drug Delivery Research Articles

In situ biodegradable crosslinking of cationic oligomer coating on mesoporous silica nanoparticles for drug delivery

Although layer-by-layer assembly using anionic and cationic polymer has been a popular way to develop core-shell nanoparticles, the strong electrostatic interactions may limit shell degradability, thus hampering their application as a platform for controlled therapeutic delivery. In this study, we demonstrate a simple approach to developing mesoporous nanohybrids via a process of pre-drug loading (using doxorubicin (DOX) as a model drug) into mesoporous silica nanoparticles (MSN), followed by surface functionalization with a kind of cationic oligomer (low molecular weight polyethylene imine, LPEI) and in situ crosslinking by degradable N,N′-bis(acryloyl)cystamine (BAC). The presence of LPEI shell affords the nanohybrids with charge-reversal ability, which means that the acidic tumor extracellular microenvironment can transform the negative surface charge at neutral conditions into positive-charged ones. The nanohybrids displayed a pH- and redox-dual sensitivity in DOX release under conditions that mimic intracellular reductive conditions and acidic tumor microenvironments. The nanohybrids can be effectively internalized into A549 cells (a carcinomic human alveolar basal epithelial cell line), resulting in a high DOX intracellular accumulation and an improved anticancer cytotoxicity when compared with free DOX, suggesting their high potential as a new platform for therapeutic delivery.

Mesoporous silica nanoparticles for stimuli-responsive controlled drug delivery: advances, challenges, and outlook.

With the development of nanotechnology, the application of nanomaterials in the field of drug delivery has attracted much attention in the past decades. Mesoporous silica nanoparticles as promising drug nanocarriers have become a new area of interest in recent years due to their unique properties and capabilities to efficiently entrap cargo molecules. This review describes the latest advances on the application of mesoporous silica nanoparticles in drug delivery. In particular, we focus on the stimuli-responsive controlled release systems that are able to respond to intracellular environmental changes, such as pH, ATP, GSH, enzyme, glucose, and H2O2. Moreover, drug delivery induced by exogenous stimuli including temperature, light, magnetic field, ultrasound, and electricity is also summarized. These advanced technologies demonstrate current challenges, and provide a bright future for precision diagnosis and treatment.

Synthesis and drug delivery of mesoporous silica nanoparticles for cancer therapy

In the past decade, mesoporous silica nanoparticles (MSNs) have attracted more and more attention for their potential biomedical applications. With their high surface area and tailored mesoporous structure, MSNs as drug delivery systems (DDSs) show significant advantages over traditional drug nanocarriers. In this review, we discuss the progress in the synthesis and drug delivery of mesoporous silica nanoparticles for cancer therapy. The review also explains their multifunctional counterparts as drug carriers and the prominent achievements using mesoporous silica nanoparticles in drug delivery.

Esterase- and pH-responsive poly(β-amino ester)-capped mesoporous silica nanoparticles for drug delivery.

Gating of mesoporous silica nanoparticles (MSNs) with the stimuli-responsive poly(β-amino ester) has been achieved. This hybrid nanocarrier releases doxorubicin (DOX) under acidic conditions or in the presence of porcine liver esterase. The DOX loaded poly(β-amino ester)-capped MSNs reduce cell viability when tested on MDA-MB-231 human breast cancer cells.

Tannin as a gatekeeper of pH-responsive mesoporous silica nanoparticles for drug delivery

Tannin grafted on mesoporous silica nanoparticles (tannin-MSNs) was synthesized by the amidation reaction of carboxyl benzyl borate with amino group modified MSN.

Fabrication of single-hole glutathione-responsive degradable hollow silica nanoparticles for drug delivery.

In the present study, a kind of single-hole glutathione (GSH)-responsive degradable hollow silica nanoparticles (G-DHSNs) was synthesized and used as carriers of doxorubicin (DOX) (DOX-G-DHSNs). The G-DHSNs were accurately designed and fabricated with a simple and convenient method, and without any extra pernicious component. The composition, morphology and properties of the G-DHSNs had been characterized by (1)HNMR spectra, Fourier transform infrared spectrograph, thermo gravimetric analysis, transmission electron microscope, and scanning electron microscope. The degradation study of G-DHSNs showed that the G-DHSNs would be broken into pieces after interacting with GSH. Besides, the negligible hemolytic activity and low cytotoxicity of the G-DHSNs demonstrated its excellent biocompatibility. pH- and GSH-triggered release of DOX followed by the decomposition of G-DHSNs within TCA8113 cancer cells was further confirmed by flow cytometry and confocal laser scanning microscopy studies. All of these results indicated that G-DHSNs can be used as safe and promising drug nanocarriers.

Hyaluronic Acid Functionalized Porous Silica Nanoparticles for Drug Delivery and Release

In this paper, we reported a facile strategy to synthesize hyaluronic acid (HA) conjugated porous silica nanoparticles (pSiO2) as drug carrier. The pSiO2 were prepared by solid nano-silica nanoparticles with “surface-protected etching”. Morphologies of solid and porous silica nanoparticles were characterized by SEM and TEM. Amino groups were introduced on pSiO2 to graft HA as cancer targeting ligand. Then rifampicin used as model drug was loaded in pSiO2-HA. The results indicate that pSiO2 can perform a certain degree of slow release. Overall, the system might open the door to a new generation of carrier system for site-selective, controlled-release delivery of anticancer drugs.

Synthesis of Mesoporous Silica Nanoparticles for Drug Delivery

Mesoporous silica nanoparticles (MSNs) is an attractive candidate as a drug delivery carrier due to their large surface area, high pore volume and t intrinsic biocompatibility. Here, MSNs were synthesized by the hydrolysis and condensation of tetraethyl orthosilicate (TEOS) with cetyltrimethylammonium bromide (CTAB) acting as structural directing agent. A large mesopore with diameter of 3.8 to 5.5 nm of MCM-41style can be obtained via the addition of 1,3,5-trimethylbenzene. Metoprolol tartrate as a selective β1 receptor blocker was embedded on MSNs by the incipient wetness impregnation. The delivery profiles were collected in vitro in SBF at pH 7.4. A close correlation can be observed between the drug release kinetic and the mesopore size and specific surface area of MSNs.

Coordination Polymer Coated Mesoporous Silica Nanoparticles for pH‐Responsive Drug Release

Coordination polymer coated mesoporous silica nanoparticles for drug delivery are successfully synthesized. The system ensures that drugs are stored in the mesopores under a physiological environment. Upon H(+) stimulus in the endosomal and lysosomal compartments, the drugs are released into the intracellular organelles of cancer cells, effectively killing the cells.

Recent Patents on the Synthesis and Application of Silica Nanoparticles for Drug Delivery

Drug delivery systems are designed to improve therapy efficacy as well as patient compliance. This could be accomplished by specifically targeting a medication intact to its active site, therefore reducing side-effects and enabling high local drug concentrations. Silica nanoparticles have gained ground in the biomedical field for their biocompatibility and biodegradability, being themselves inert and stable, thus enabling a variety of formulation designs for application in the pharmaceutical industry. This paper is a review of the recent patents on the applications of silica nanoparticles for drug delivery and their preparation. The review will focus on the different techniques available to obtain silica nanoparticles with variable morphology and their drug targeting applications, providing an overview of silica particles synthesis described in the literature.

Live-Cell Imaging of Colloidal Mesoporous Silica Nanoparticles for Drug Delivery: Drug Loading, Pore Sealing and Controlled Release

Colloidal mesoporous silica (CMS) nanoparticles are promising candidates for drug delivery. However, after the drug is loaded into the pores, sealing of the pores against premature drug release and controlled intracellular drug release are challenging tasks. We studied the mechanisms of nanoparticle uptake into living cells, trafficking and intracellular delivery of drugs by highly-sensitive fluorescence microscopy and real-time single-particle tracking. As an approach to seal the mesopores, we encapsulated CMS nanoparticles of 50 nm diameter with a supported lipid bilayer (SLB). We demonstrated the delivery of the microtubule-depolymerising drug colchicine from SLB-coated CMS nanoparticles into liver cancer cells. The microtubule network of the cells was destroyed within 2 h of incubation. With this method, colchicine is released directly into the cell showing characteristic effects at concentrations below the amount necessary for application in solution. In another approach, we linked a fluorescently labelled model drug (cystein-ATTO633) via a redox-sensitive disulfide bridge inside the pores of CMS. For reduction of the disulfide bonds and release of the drug, the CMS nanoparticles need to reach the cytoplasmic reducing milieu after internalization. We showed that nanoparticles were endocytosed by HuH7 cells, but endosomal escape seems to be a bottleneck for drug release. Using a photosensitizer to induce endosomal escape, successful release of the drug was achieved. Additionally, we found that grafting of ATTO633 at high concentration in the pores of silica nanoparticles results in self-quenching of the ATTO633 fluorescence. Release of dye from the pores promotes a de-quenching effect with an excellent readout signal. As the EGF-receptor is overexpressed on a variety of tumors, CMS particles were equipped with EGF as ligand for specific targeting. Internalization and cellular motion of the particles was studied by single-particle tracking.

Saccharide-sensitive mesoporous silica nanoparticles for drug delivery

Saccharide-sensitive mesoporous silica nanoparticles for drug delivery

Lipid-coated silica nanoparticles for drug delivery, gene therapy and molecular imaging

Lipid-coated silica nanoparticles for drug delivery, gene therapy and molecular imaging